Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269316 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Impact Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 8
- Study locations
NCT05269316: Recruiting Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Impact Therapeutics.
NCT05269316 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by Impact Therapeutics. The registered enrollment target is 61 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05269316, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by Impact Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
Primary Outcome
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs)
Conditions Studied
Interventions
- DRUG IMP9064
Study Locations (8)
Other
- Linear Clinical Research Limited - Nedlands
- National Taiwan University Hospital - Taipei
New Jersey
- Hackensack University Medical Center PARTNER - Hackensack
New York
- Mount Sinai - New York
South Carolina
- Greenville Hospital System University Medical Center (ITOR) - Greenville
Texas
- Mary Crowley Cancer Research Centers - Dallas
New South Wales
- Blacktown Hospital - Blacktown
Beijing Municipality
- Beijing Cancer Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05269316 shows while recruiting
NCT05269316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMP9064 is the first listed.
NCT05269316 lists 8 locations in 7 states (Other, New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT05269316 about?
NCT05269316 is a clinical study titled "Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors". This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
What is the current status of trial NCT05269316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-02-11. Estimated completion is 2026-12-31.
What conditions does trial NCT05269316 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.
What interventions are being tested in trial NCT05269316?
The interventions under investigation include: IMP9064 (DRUG).
Who is sponsoring clinical trial NCT05269316?
This trial is sponsored by Impact Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05269316 being conducted?
This trial has 8 study locations across New Jersey, New York, South Carolina, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05269316's enrollment target sits among peer trials
61 109th of 196 higher than 88 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05593653 · 61 participants · Phase 4
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI